Create an Account
  1. Home
  2. Specialty
  3. Retina

Innovate Retina: Spotlight on Ocular Oncology Part 1

Innovate Retina Spotlight on Ocular Oncology Part 1
Media formats available:
Details

  • Overview

    Innovate – Retina, The Stanford Innovation Summit series will take place virtually over the course of three virtual meetings. The summit focuses exclusively on game-changing innovations in medical and surgical retina, including current management of age-related macular degeneration (AMD) and diabetic retinopathy, ocular imaging, gene therapy, ocular inflammation, surgical technologies, ocular oncology and the latest advances in retinal pharmacotherapy. This webinar captured from the first virtual meeting is part one of two parts. 

    Supported by educational grants from Alcon Vision, Apellis, Carl Zeiss Meditec, Genentech, a member of the Roche Group. REGENXBIO and Regeneron Pharmaceuticals.

  • Learning Objectives

    Upon completion of this activity, the participant should be able to:

    • Discuss the unmet needs in the management of retinal vascular diseases including radiation retinopathy
    • Identify diagnostic and therapeutic targets in intraocular tumors such as uveal melanoma, retinoblastoma, lymphoma, and orbital tumors
    • Assess innovations across imaging, medical devices, artificial intelligence, and pharmacotherapeutics

    • Accreditation

      Jointly Provided by Evolve Medical Education and iVista Medical Education.

      ACCREDITATION AND DESIGNATION

      This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Evolve Medical Education LLC and iVista Medical Education. Evolve Medical Education LLC is accredited by the ACCME to provide continuing medical education for physicians.

       

      Evolve Medical Education LLC designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    • Participation Method

      In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.

    • Faculty and Disclosures

      DISCLOSURE POLICY
      It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.

      DISCLOSURE POLICY
      It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.

      The following faculty/staff members have the following financial relationships with commercial interests:

      Thomas Aaberg, MD,has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant:Castle Biosciences.

      Jessie Berrie, MD,has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Castle Biosciences.

      Zelia Maria Correa, MD, PhD,has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Grant/Research Support: Castle Biosciences.

      Diana Do, MD,has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Boehringer Ingelheim, Kodiak Sciences, Mallinckrodt, Novartis, and Regeneron Pharmaceuticals.  Grant/Research Support: Boehringer Ingelheim, Novartis and Regeneron Pharmaceuticals. Stock/Shareholder: Kodiak Sciences

      Jasmine Francis, MD,has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Grant/Research Support:  Knights Templar Eye Foundation, Macula Society.

      Dan S. Gombos, MD,has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Aura Biosciences, Castle Biosciences, 3T Ophthalmic, Putnam Consultants, and Seattle Genetics. Grant/Research Support: Houseman/Wilkins Ophthalmological Foundation, Lois Kuss Foundation for Genetic Research.

      Elin Gray, PhD,has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Grant/Research Support: Ideaya Biosciences, MSD. Speaker’s Bureau: Bio-RAD, MSD.

      J. William Harbour, MD,has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Castle Biosciences.

      Ivana K. Kim, MD,has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Biophytis, Castle Biosciences, Kodiak Sciences, Novartis. Grant/Research Support: Allergan.

      Miguel A.  Materin, MD,has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: AstraZeneca, Castle Biosciences. Speaker’s Bureau: Carl Zeiss Meditec.

      Prithvi Mruthyunjaya, MD, MHS,has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alcon, and Castle Biosciences.

      Quong Dong Nguyen, MD, MSc,has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Asciepix, Regeneron Pharmaceuticals, Rezolute, and Santen.  Grant/Research Support: Genentech, Gilead, Novartis, Regeneron Pharmaceuticals and Santen.

      Manoj Parulekar, MD, FRCS,has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Altacor UK, Oxular UK.

      Carol Shields, MD,has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Immunocare. Grant/Research Support: Aura Biosciences.

      Alison Skalet, MD, PhD,has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Castle Biosciences.

      Arun Singh, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Isoaid, LLC. Stock/Shareholder: Aura Biosciences.

      Stephen Smith, MD,has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Oncopeptides. Stock/Shareholder: iRenix Medical.

      The following faculty have no financial relationships with commercial interests:  Brenda Gallie, MD; Andrea L. Kossler, MD; Brian P. Marr, MD; Daniel Martin, MD; Vinit Mahajan, MD, PhD; Rajesh Rao, MD; Mandeep Sagoo, MB, BChir, PhD.

       

      EDITORIAL

      The Evolve staff and planners have no financial relationships with commercial interests. iVista staff and planners have no financial relationships with commercial interests. Nisha Mukherjee, MD, peer reviewer, has no financial relationships with commercial interests.

      .

    • Disclaimer

      OFF-LABEL STATEMENT
      This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

      DISCLAIMER
      The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, iVista, Alcon Vision, Apellis, Carl Zeiss Meditec, Genentech, a member of the Roche Group. REGENXBIO and Regeneron Pharmaceuticals.

    • System Requirements

      • Supported Browsers (2 most recent versions):
        • Google Chrome for Windows, Mac OS, iOS, and Android
        • Apple Safari for Mac OS and iOS
        • Mozilla Firefox for Windows, Mac OS, iOS, and Android
        • Microsoft Edge for Windows
      • Recommended Internet Speed: 5Mbps+

    • Publication Dates

      Release Date:

      Expiration Date:

    Ready to Claim Your Credits?

    You have attempts to pass this post-test. Take your time and review carefully before submitting.

    Good luck!

    LIVE ON REACHMD RADIOBack to live radio
    ReachMD Radio

    Loading...

    00:00
    00:00
      Register

      We're glad to see you're enjoying Evolve Medical Education…
      but how about a more personalized experience?

      Register for free